University Health Network, Toronto: Multiple Myeloma trials

The registry lists 11 Multiple Myeloma studies with University Health Network, Toronto as lead sponsor. 3 are open to participants now and 1 have results posted.

Phase 1 2Phase 2 6Phase 3 1Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)RecruitingNCT06871176Not applicable
• Early Palliative Care for Patients With Multiple Myeloma and Aggressive LymphomaRecruitingNCT06485076Not applicable
• Plan Development for Giving Teclistamab in the Outpatient SettingRecruitingNCT06251076Phase 4
• A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple MyelomaTerminatedNCT01672736Phase 1/2Results posted
• A Study to Desensitize Allergic Reactions to Treatments for Blood DisordersCompletedNCT03959358Phase 2
• Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of ImprovementTerminatedNCT02952573Phase 2
• Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide MaintenanceCompletedNCT01702831Phase 2
• Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure PatientsCompletedNCT01270932Phase 2
• Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on ChemotherapyCompletedNCT01016548Phase 3
• Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological MalignancyTerminatedNCT00963495Phase 1
• Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple MyelomaCompletedNCT00570180Phase 2